Log In Sign up
The largest database of trusted experimental protocols

Ve 822

Manufactured by MedKoo Biosciences
Visit Supplier
Sourced in United States, Germany

VE-822 is a laboratory equipment used for experimental purposes. It functions as an ATR kinase inhibitor.

Automatically generated - may contain errors

Lab products found in correlation

Mk 8776, by Selleck Chemicals (2 mentions) Azd6738, by MedKoo Biosciences (2 mentions) Ly2603618, by Selleck Chemicals (2 mentions) Azd6738, by Adooq (1 mentions) 5 fluouracil 5 fu, by Merck Group (1 mentions) Mitomycin c mmc, by Merck Group (1 mentions)

2 protocols using ve 822

1

Cell Line-Based Anticancer Drug Evaluation

Check if the same lab product or an alternative is used in the 5 most similar protocols
AZD6738 and VE-822 were purchased from MedKoo Biosciences (Morrisville, NC, USA), MK-8776 and LY2603618 from Selleckchem (Munich, Germany), and MMC and 5-FU from Sigma-Aldrich (Hamburg, Germany). Oxaliplatin and carboplatin were kindly donated from the cytostatic drug department of the University Hospital Marburg. AZD6738, used in the xenograft in vivo assay, was purchased from AdooQ Bioscience (Irvine, CA, USA).
Job A., Tatura M., Schäfer C., Lutz V., Schneider H., Lankat-Buttgereit B., Zielinski A., Borgmann K., Bauer C., Gress T.M., Buchholz M, & Gallmeier E. (2020). The POLD1R689W variant increases the sensitivity of colorectal cancer cells to ATR and CHK1 inhibitors. Scientific Reports, 10, 18924.
+ Open protocol
+ Expand
2

Cytotoxic Reagents Acquisition Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
AZD6738 and VE-822 were purchased from MedKoo Biosciences (Morrisville, NC), MK-8776 and LY2603618 from Selleckchem (Munich, Germany), and mitomycin C (MMC) and 5-fluouracil (5-FU) from Sigma-Aldrich (Hamburg, Germany). Oxaliplatin was kindly donated from the cytostatic drug department of the University Hospital Marburg.
Job A., Schmitt L.M., von Wenserski L., Lankat-Buttgereit B., Gress T.M., Buchholz M, & Gallmeier E. (2018). Inactivation of PRIM1 Function Sensitizes Cancer Cells to ATR and CHK1 Inhibitors. Neoplasia (New York, N.Y.), 20(11), 1135-1143.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!